Enhancing treatment for mucosal melanoma using a modified virus
Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMV
This study is exploring a new way to treat mucosal melanoma using a modified virus that could help your immune system fight the cancer better, with the goal of finding a safer and more effective treatment for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11073845 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating mucosal melanoma by utilizing a modified version of the lymphocytic choriomeningitis virus (r3LCMV). The study aims to harness the virus's ability to trigger strong immune responses against tumors, potentially improving the effectiveness of cancer therapies. By testing this approach in both animal models and human applications, the researchers hope to develop a safer and more effective treatment option for patients with this aggressive form of melanoma. The project will focus on the virus's direct effects on tumor cells and its ability to stimulate the immune system.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with mucosal melanoma or those who may benefit from innovative cancer immunotherapies.
Not a fit: Patients with non-melanoma skin cancers or those who do not have mucosal melanoma may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with mucosal melanoma.
How similar studies have performed: Previous research has shown promising results with viral-based therapies for cancer, indicating potential success for this novel approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Pollack, Seth M — Northwestern University at Chicago
- Study coordinator: Pollack, Seth M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.